Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Nutrients ; 13(10)2021 Oct 12.
Artigo em Inglês | MEDLINE | ID: mdl-34684574

RESUMO

An herbal mixture composed of lemon, apple cider, garlic, ginger and honey as a polyphenol-rich mixture (PRM) has been reported to contain hypolipidemic activity on human subjects and hyperlipidemic rats. However, the therapeutic effects of PRM on metabolites are not clearly understood. Therefore, this study aimed to provide new information on the causal impact of PRM on the endogenous metabolites, pathways and serum biochemistry. Serum samples of hyperlipidemic rats treated with PRM were subjected to biochemistry (lipid and liver profile) and hydroxymethylglutaryl-CoA enzyme reductase (HMG-CoA reductase) analyses. In contrast, the urine samples were subjected to urine metabolomics using 1H NMR. The serum biochemistry revealed that PRM at 500 mg/kg (PRM-H) managed to lower the total cholesterol level and low-density lipoprotein (LDL-C) (p < 0.05) and reduce the HMG-CoA reductase activity. The pathway analysis from urine metabolomics reveals that PRM-H altered 17 pathways, with the TCA cycle having the highest impact (0.26). Results also showed the relationship between the serum biochemistry of LDL-C and HMG-CoA reductase and urine metabolites (trimethylamine-N-oxide, dimethylglycine, allantoin and succinate). The study's findings demonstrated the potential of PRM at 500 mg/kg as an anti-hyperlipidemic by altering the TCA cycle, inhibiting HMG-CoA reductase and lowering the LDL-C in high cholesterol rats.


Assuntos
Citrus/química , Alho/química , Mel , Hiperlipidemias/metabolismo , Hiperlipidemias/terapia , Malus/química , Metaboloma , Preparações de Plantas/uso terapêutico , Zingiber officinale/química , Animais , Hidroximetilglutaril-CoA Redutases/metabolismo , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Hiperlipidemias/sangue , Hiperlipidemias/urina , Análise dos Mínimos Quadrados , Lipoproteínas LDL/metabolismo , Redes e Vias Metabólicas/efeitos dos fármacos , Polifenóis/farmacologia , Análise de Componente Principal , Espectroscopia de Prótons por Ressonância Magnética , Ratos Wistar
2.
J Sep Sci ; 44(17): 3305-3318, 2021 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-34185383

RESUMO

Hyperlipidemia is recognized as one of the most important risk factors for morbidity and mortality due to cardiovascular diseases. Daming capsule, a Chinese patent medicine, has shown definitive efficacy in patients with hyperlipidemia. In this study, serum biochemistry and histopathology assessment were used to investigate the lipid-lowering effect of Daming capsule. Furthermore, urinary metabolomics based on ultra high performance liquid chromatography with quadrupole time-of-flight mass spectrometry was conducted to identify the urinary biomarkers associated with hyperlipidemia and discover the underlying mechanisms of the antihyperlipidemic action of Daming capsule. After 10 weeks of treatment, Daming capsule significantly lowered serum lipid levels and ameliorated hepatic steatosis induced by a high-fat diet. A total of 33 potential biomarkers associated with hyperlipidemia were identified, among which 26 were robustly restored to normal levels after administration of Daming capsule. Pathway analysis revealed that the lipid-lowering effect of Daming capsule is related to the regulation of multiple metabolic pathways including vitamin B and amino acid metabolism, tricarboxylic acid cycle, and pentose phosphate pathway. Notably, the study demonstrates that metabolomics is a powerful tool to elucidate the multitarget mechanism of traditional Chinese medicines, thereby promoting their research and development.


Assuntos
Medicamentos de Ervas Chinesas/análise , Hiperlipidemias/urina , Hipolipemiantes/análise , Metabolômica , Substâncias Protetoras/análise , Substâncias Protetoras/uso terapêutico , Administração Oral , Animais , Cápsulas/análise , Cápsulas/metabolismo , Cápsulas/uso terapêutico , Cromatografia Líquida de Alta Pressão , Dieta Hiperlipídica/efeitos adversos , Medicamentos de Ervas Chinesas/metabolismo , Medicamentos de Ervas Chinesas/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Hiperlipidemias/metabolismo , Hipolipemiantes/metabolismo , Hipolipemiantes/uso terapêutico , Masculino , Espectrometria de Massas , Substâncias Protetoras/metabolismo , Ratos , Ratos Wistar , Software , Fatores de Tempo
3.
J Pharm Biomed Anal ; 156: 104-115, 2018 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-29698861

RESUMO

Hyperlipidemia has been highlighted to be one of the most prominent and global chronic condition nowadays. Daming capsule (DMC), a traditional Chinese medicine (TCM) preparation, has treated hyperlipidemia on clinic in China for decades. Our recent study showed that aloe-emodin (AE) is one of the main bioactive components in DMC. Therefore, the present study aims to further investigate the lipid-lowering effect by serum biochemistry and histopathological examination, and reveal the underlying mechanisms by urinary metabolomics approach. After oral administration of AE for 6 weeks, the total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-c) levels in 50 and 100 mg/kg AE groups were both decreased significantly (P < 0.05 and P < 0.001). An ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry (UPLC-ESI-QTOF-MS) followed by principal components analysis (PCA), partial least squares- discriminant analysis (PLS-DA), orthogonal partial least squares-discriminant analysis (OPLS-DA), correlation analysis, heat map, and KEGG pathways was employed to identify 26 potential biomarkers. Twenty three among them were restored by AE including L-citrulline, 6-methylaminopurine, imidazoleacetic acid riboside, N-acetylhistamine, 3-methyladenine, 1-methyladenosine, dopamine, N1-methyl-4-pyridone-3-carboxamide, formylanthranilic acid, 4-pyridoxate, cAMP, salsolinol, isethionate, d-ribonic acid, 3-sulfolactic acid, vitamin C, mesaconic acid, sulfosalicylic acid, salicyluric acid, N-acetylanthranilic acid, 4,6- Dihydroxyquinoline, sebacic acid and hyocholic Acid. The related metabolic pathways include TCA cycle, the metabolism of amino acids, taurine, B vitamins, purines and pyrimidines. The results indicate that AE has a favorable therapeutic effect on HFD-induced hyperlipidemia by adjusting the metabolic disorders. Notably, urinary metabolomics combined with pattern recognition analysis provides a powerful and reliable approach into the research and development of TCM and phytochemicals.


Assuntos
Antraquinonas/farmacologia , Medicamentos de Ervas Chinesas/farmacologia , Hiperlipidemias/tratamento farmacológico , Metaboloma/efeitos dos fármacos , Metabolômica/métodos , Animais , Antraquinonas/uso terapêutico , Biomarcadores/urina , Cromatografia Líquida de Alta Pressão , Dieta Hiperlipídica/efeitos adversos , Modelos Animais de Doenças , Medicamentos de Ervas Chinesas/uso terapêutico , Humanos , Hiperlipidemias/etiologia , Hiperlipidemias/metabolismo , Hiperlipidemias/urina , Metabolismo dos Lipídeos/efeitos dos fármacos , Lipídeos/sangue , Masculino , Redes e Vias Metabólicas/efeitos dos fármacos , Ratos , Ratos Wistar , Espectrometria de Massas em Tandem
4.
Biomed Chromatogr ; 31(4)2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27571931

RESUMO

Rhizoma Alismatis (RA), a diuretic in Asia and Europe, was found to possess anti-hyperlipidemic activity. Since the biomarkers and mechanisms of RA in the treatment of hyperlipidemia are inadequate, ultra-performance liquid chromatography coupled with quadrupole time-of-flight synapt high-definition mass spectrometry and multivariate data analysis were employed to investigate the urinary metabolomics of RA on hyperlipidemic rats induced by high-fat diet. The metabolic profile of RA-treated hyperlipidemic group located between control and diet-induced hyperlipidemic groups. Nineteen metabolites with significant fluctuations were identified as potential biomarkers related to the hyperlipidemia and anti-hyperlipidemia of RA using partial least-squares-discriminate analysis, heatmap analysis and correlation coefficient analysis. The fluctuations of these biomarkers represented disturbances in amino acid metabolism, purine metabolism, pyrimidine metabolism and energy metabolism. After RA treatment, these perturbed metabolites were restored to normal or nearly normal levels. RA can alleviate high-fat diet-induced dysfunctions in these metabolic pathways.


Assuntos
Alisma/química , Biomarcadores/urina , Hiperlipidemias/tratamento farmacológico , Hiperlipidemias/urina , Hipolipemiantes/farmacologia , Animais , Biomarcadores/metabolismo , LDL-Colesterol/sangue , Cromatografia Líquida/métodos , Dieta Hiperlipídica/efeitos adversos , Hiperlipidemias/etiologia , Hipolipemiantes/química , Análise dos Mínimos Quadrados , Masculino , Espectrometria de Massas , Análise Multivariada , Plantas Medicinais/química , Ratos Sprague-Dawley , Reprodutibilidade dos Testes , Rizoma/química , Triglicerídeos/sangue
5.
J Agric Food Chem ; 64(9): 1879-88, 2016 Mar 09.
Artigo em Inglês | MEDLINE | ID: mdl-26889783

RESUMO

The effects of virgin olive oil (VOO) enriched with its own phenolic compounds (PC) and/or thyme PC on the protection against oxidative DNA damage and antioxidant endogenous enzymatic system (AEES) were estimated in 33 hyperlipidemic subjects after the consumption of VOO, VOO enriched with its own PC (FVOO), or VOO complemented with thyme PC (FVOOT). Compared to pre-intervention, 8-hydroxy-2'-deoxyguanosine (a marker for DNA damage) decreased in the FVOO intervention and to a greater extent in the FVOOT with a parallel significant increase in olive and thyme phenolic metabolites. Superoxide dismutase (AEES enzyme) significantly increased in the FVOO intervention and to a greater extent in the FVOOT with a parallel significant increase in thyme phenolic metabolites. When all three oils were compared, FVOOT appeared to have the greatest effect in protecting against oxidative DNA damage and improving AEES. The sustained intake of a FVOOT improves DNA protection against oxidation and AEES probably due to a greater bioavailability of thyme PC in hyperlipidemic subjects.


Assuntos
Dano ao DNA/efeitos dos fármacos , Alimentos Fortificados/análise , Hiperlipidemias/tratamento farmacológico , Azeite de Oliva/química , Fenóis/administração & dosagem , Thymus (Planta)/química , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Antioxidantes/administração & dosagem , Antioxidantes/metabolismo , Biomarcadores/sangue , Estudos Cross-Over , DNA/metabolismo , Método Duplo-Cego , Eritrócitos/química , Feminino , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/urina , Masculino , Pessoa de Meia-Idade , NF-kappa B/metabolismo , Oxirredução , Estresse Oxidativo/efeitos dos fármacos , Fenóis/sangue , Fenóis/urina , Ratos , Ratos Wistar , Superóxido Dismutase/sangue
6.
Curr Opin Investig Drugs ; 2(3): 393-5, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11575711

RESUMO

S-8921 is a sodium/bile acid transport inhibitor under development by Shionogi for the potential treatment of hyperlipidemia. As of June 2000, phase I trials had commenced in Japan and were planned in Europe [370602]. S-8921 acts by altering sodium-dependent transport mechanisms of the brush-borders in the intestinal mucosa, causing bile acids that re-enter the intestine to be excreted rather than reabsorbed [281476].


Assuntos
Anticolesterolemiantes/farmacologia , Ácidos e Sais Biliares/metabolismo , Proteínas de Transporte/antagonistas & inibidores , Drogas em Investigação , Hidroxiesteroide Desidrogenases , Glicoproteínas de Membrana , Naftóis/farmacologia , Animais , Anticolesterolemiantes/uso terapêutico , Transporte Biológico/efeitos dos fármacos , Ensaios Clínicos Fase I como Assunto , Avaliação Pré-Clínica de Medicamentos , Previsões , Glucuronídeos/metabolismo , Humanos , Hiperlipidemias/sangue , Hiperlipidemias/tratamento farmacológico , Hiperlipidemias/urina , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Estrutura Molecular , Naftóis/química , Naftóis/farmacocinética , Naftóis/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA